240 related articles for article (PubMed ID: 30239824)
1. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
[TBL] [Abstract][Full Text] [Related]
2. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
[TBL] [Abstract][Full Text] [Related]
3. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
4. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution.
Hwang GS; Paranjpe R; Opsomer C; Lu K; Abajue U; Abughosh S; Zaghloul H; Trivedi MV
Clin Breast Cancer; 2020 Dec; 20(6):520-526. PubMed ID: 32669209
[TBL] [Abstract][Full Text] [Related]
5. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
[TBL] [Abstract][Full Text] [Related]
6. Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer.
Reeder-Hayes KE; Mayer SE; Lund JL
Cancer; 2021 Apr; 127(8):1220-1227. PubMed ID: 33508140
[TBL] [Abstract][Full Text] [Related]
7. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
[TBL] [Abstract][Full Text] [Related]
8. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
9. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.
Aiello Bowles EJ; Boudreau DM; Chubak J; Yu O; Fujii M; Chestnut J; Buist DS
J Oncol Pract; 2012 Nov; 8(6):e149-57. PubMed ID: 23598850
[TBL] [Abstract][Full Text] [Related]
11. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
12. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors.
Spencer JC; Reeve BB; Troester MA; Wheeler SB
Psychooncology; 2020 Apr; 29(4):647-654. PubMed ID: 32048400
[TBL] [Abstract][Full Text] [Related]
15. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
16. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM
J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232
[TBL] [Abstract][Full Text] [Related]
17. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
18. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
Hershman DL; Tsui J; Meyer J; Glied S; Hillyer GC; Wright JD; Neugut AI
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25349080
[TBL] [Abstract][Full Text] [Related]
19. Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.
Neugut AI; Zhong X; Wright JD; Accordino M; Yang J; Hershman DL
JAMA Oncol; 2016 Oct; 2(10):1326-1332. PubMed ID: 27281650
[TBL] [Abstract][Full Text] [Related]
20. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]